Clintec Revenue and Competitors
Estimated Revenue & Valuation
- Clintec's estimated annual revenue is currently $62.3M per year.
- Clintec's estimated revenue per employee is $201,000
Employee Data
- Clintec has 310 Employees.
- Clintec grew their employee count by -16% last year.
Clintec's People
Name | Title | Email/Phone |
---|---|---|
1 | Associate Director | Reveal Email/Phone |
2 | Associate Director Clinical Operations | Reveal Email/Phone |
3 | Associate Director ClinOp MSD Assigment | Reveal Email/Phone |
4 | Associate Director Clinical Operations | Reveal Email/Phone |
5 | Associate Director, Clinical Operations Line Manager at Clintec (on assignment for MSD) | Reveal Email/Phone |
6 | Regional Director | Reveal Email/Phone |
7 | Project Finance Manager | Reveal Email/Phone |
8 | Executive Administration Manager | Reveal Email/Phone |
9 | Country Clinical Quality Manager on assignment to MSD | Reveal Email/Phone |
10 | Clinical Operations Manager | Reveal Email/Phone |
Clintec Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $5.8M | 23 | -12% | N/A | N/A |
#2 | $4.1M | 30 | -19% | N/A | N/A |
#3 | $71M | 300 | -3% | N/A | N/A |
What Is Clintec?
Clintec is an innovative, medium-sized, woman-owned, global Contract Research Organization providing global full and functional service support to the pharmaceutical, biotechnology and medical device industries. We are headquartered in the UK and have grown our clinical research business organically over the past 20 years. What We Do We are a global contract clinical research organisation that works with the best clinical experts to deliver a unique mix of technical, operational and scientific expertise in drug development. Where people's lives are involved, there's always more to be done, innovation to be discovered. We turn ideas into reality to meet patients needs to bring new medicines to market. We use e-clinical technologies to see the big picture in the smallest detail and provide a customized clinical service ensuring excellence at every stage. Why Choose Clintec At Clintec we believe flexibility is the key to success when working with our clients. We endeavor to meet our clients needs by being proactive and have created an environment that fosters this approach with our teams. Based in over 50 countries , our expertise is vast, yet our approach is simple: were focused, flexible and forward-thinking. FOCUSED: In clinical research every second counts. We take time to get things right first time. We see the bigger picture even while scrutinizing the smallest of details. FLEXIBLE: Every challenge is different, so every solution should be different too. We bring together a customized team for each challenge. We tailor our services to not just meet expectations, but exceed them. FORWARD THINKING: Were leaders, not followers. If there's a way to make something happen, well find it. Impossible isnt in our vocabulary.
keywords:N/AN/A
Total Funding
310
Number of Employees
$62.3M
Revenue (est)
-16%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Clintec News
... PSI, ICON plc, IQVIA, Med pace, Parexel International Corporation, KCR S.A, PRA Health Sciences Clintec, Pharmaceutical Product Development, LLC.
Accenture, C3i Solutions, Clintec, Covance, Deloitte Touche Tohmatsu Limited, ELC Group, Ergomed, iGATE Corporation, iMED Global Corporation, IQVIA,...
... IQVIA, Med pace, Parexel International Corporation, KCR S.A, PRA Health Sciences Clintec, Pharmaceutical Product Development, LLC.
ClinTec International, a global Clinical Research Organisation, received an £8m majority investment from London AIM market listed private equity firm Elephant Capital plc. Through this investment, Elephant has acquired a significant minority stake in the company. Managing Partner of Elephant Ca ...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $84M | 320 | N/A | N/A |
#2 | $85.3M | 325 | 66% | N/A |
#3 | $75.2M | 334 | 9% | N/A |
#4 | $15M | 335 | N/A | N/A |
#5 | $41.9M | 335 | 9% | N/A |